Maria Infantino Selected Research

Biosimilar Pharmaceuticals

7/2022	Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease.
1/2017	Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maria Infantino Research Topics

Disease

28	Rheumatoid Arthritis 03/2024 - 01/2013
20	Rheumatic Diseases (Rheumatism) 11/2023 - 01/2013
12	COVID-19 03/2024 - 01/2020
9	Autoimmune Diseases (Autoimmune Disease) 05/2023 - 12/2015
8	Arthritis (Polyarthritis) 12/2022 - 01/2017
6	Connective Tissue Diseases (Connective Tissue Disease) 05/2023 - 03/2017
6	Myositis (Idiopathic Inflammatory Myopathies) 12/2022 - 01/2018
5	Systemic Lupus Erythematosus (Libman-Sacks Disease) 05/2023 - 01/2015
5	Psoriatic Arthritis 01/2022 - 04/2016
5	Infections 11/2021 - 04/2016
4	Neoplasms (Cancer) 09/2023 - 03/2020
4	Inflammation (Inflammations) 05/2023 - 01/2021
4	Ankylosing Spondylitis 01/2020 - 01/2017
3	Muscular Diseases (Myopathy) 01/2021 - 10/2016
3	Necrosis 01/2021 - 01/2013
2	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 12/2023 - 01/2022
2	Vasculitis (Vasculitides) 05/2023 - 01/2022
2	Systemic Scleroderma (Systemic Sclerosis) 05/2023 - 12/2022
2	Crohn Disease (Crohn's Disease) 01/2023 - 01/2017
2	Celiac Disease (Celiac Sprue) 10/2021 - 01/2021
2	Pain (Aches) 01/2021 - 01/2017
2	Disease Progression 01/2021 - 01/2015
2	Hypersensitivity (Allergy) 01/2015 - 01/2013
1	Skin Neoplasms (Skin Cancer) 03/2024
1	Herpes Zoster 03/2024
1	Melanoma (Melanoma, Malignant) 03/2024
1	Fibrosis (Cirrhosis) 05/2023
1	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 05/2023
1	Adult-Onset Still's Disease 05/2023
1	Glomerulonephritis 05/2023
1	Immune System Diseases (Immune Disorders) 04/2023
1	Mixed Connective Tissue Disease (MCTD) 12/2022
1	Dermatomyositis (Dermatopolymyositis) 10/2022
1	Calcinosis 10/2022
1	Skin Manifestations 10/2022
1	Inclusion Body Myositis 10/2022
1	Livedo Reticularis 01/2022
1	Thrombocytopenia (Thrombopenia) 01/2022
1	Leukopenia 01/2022

Drug/Important Bio-Agent (IBA)

27	AntibodiesIBA 10/2023 - 01/2013
15	AutoantibodiesIBA 11/2023 - 10/2016
14	Biomarkers (Surrogate Marker)IBA 05/2023 - 04/2016
7	Leukocyte L1 Antigen Complex (Calgranulin)IBA 05/2023 - 01/2017
5	Rheumatoid FactorIBA 12/2023 - 09/2014
5	Immunoglobulin M (IgM)IBA 01/2022 - 01/2013
5	tocilizumab (atlizumab)FDA Link 01/2020 - 01/2014
4	Proteins (Proteins, Gene)FDA Link 05/2023 - 03/2020
4	Etanercept (Enbrel)FDA Link 01/2023 - 01/2013
4	Immunoglobulin G (IgG)IBA 01/2022 - 01/2015
4	Immunoglobulins (Immunoglobulin)IBA 11/2021 - 01/2015
4	Immunoglobulin A (IgA)IBA 10/2021 - 01/2013
3	Janus Kinase InhibitorsIBA 03/2024 - 01/2022
3	Urokinase Plasminogen Activator ReceptorsIBA 04/2023 - 01/2022
3	Antirheumatic Agents (DMARD)IBA 02/2023 - 01/2016
3	Antinuclear AntibodiesIBA 01/2023 - 01/2019
3	anti-dsDNA autoantibodyIBA 12/2022 - 01/2018
3	VaccinesIBA 01/2022 - 01/2021
3	Anti-Citrullinated Protein AntibodiesIBA 01/2021 - 09/2014
3	Abatacept (Orencia)FDA Link 01/2019 - 04/2016
3	Infliximab (Remicade)FDA Link 01/2018 - 01/2013
2	tofacitinibIBA 03/2024 - 01/2022
2	Interleukin-6 (Interleukin 6)IBA 03/2024 - 01/2021
2	Antiphospholipid AntibodiesIBA 12/2023 - 01/2022
2	mRNA VaccinesIBA 09/2023 - 12/2022
2	EnzymesIBA 12/2022 - 01/2017
2	COVID-19 VaccinesIBA 12/2022 - 12/2021
2	DNA (Deoxyribonucleic Acid)IBA 12/2022 - 01/2022
2	Ligases (Synthetase)IBA 10/2022 - 01/2018
2	Biosimilar PharmaceuticalsIBA 07/2022 - 01/2017
2	Messenger RNA (mRNA)IBA 01/2022 - 01/2021
2	Neutralizing AntibodiesIBA 01/2022 - 12/2021
2	BNT162 VaccineIBA 01/2022 - 12/2021
2	Rituximab (Mabthera)FDA Link 01/2021 - 08/2020
2	Intravenous Immunoglobulins (IVIG)FDA Link 01/2021 - 10/2020
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2020 - 10/2016
2	Adalimumab (Humira)FDA Link 01/2018 - 01/2013
2	Cartilage Oligomeric Matrix ProteinIBA 02/2015 - 01/2014
1	GLPG0634IBA 03/2024
1	baricitinibIBA 03/2024
1	upadacitinibIBA 03/2024
1	Calgranulin AIBA 05/2023
1	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 05/2023
1	CytokinesIBA 04/2023
1	ametantrone (HAQ)IBA 01/2023
1	N-phthaloylglutamic acidIBA 01/2023
1	beta-cyclodextrin tetradecasulfate (CTDS)IBA 12/2022
1	Plasminogen Activators (Plasminogen Activator)IBA 12/2022
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 12/2022
1	Anti-Idiotypic AntibodiesIBA 12/2022
1	RNA (Ribonucleic Acid)IBA 10/2022
1	omega-Chloroacetophenone (Mace)IBA 01/2022
1	Nuclear Antigens (Extractable Nuclear Antigens)IBA 01/2022
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2022
1	Complement System Proteins (Complement)IBA 01/2022

Therapy/Procedure

10	Therapeutics 12/2022 - 01/2015
2	Biological Therapy 04/2020 - 04/2016
1	Aftercare (After-Treatment) 03/2024
1	Radiotherapy 09/2023
1	Precision Medicine 12/2022
1	Cannula 01/2022